ArticleKidney international reports2025

Evaluating Sibeprenlimab in IgA Nephropathy - Rationale and Baseline Data from the VISIONARY Trial.

Vlado Perkovic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.